• 首页
  • 关于期刊
    期刊简介
    编委会
    青年编委会
    合作单位
    《药学研究》编辑部
  • 投稿指南
  • 制度与声明
    出版伦理规范
    学术不端声明
    开放获取(OA)声明
    AIGC工具使用声明
  • 期刊订阅
  • 下载中心
  • English
引用本文:Narh Philip Amor(阿莫),林昂.靶向PreS1的HBV mRNA疫苗的开发与免疫原性评价[J].药学研究,2024,43(11):1041-1044,1108[点击复制]
【打印本页】      【下载PDF全文】   【查看/发表评论】  【下载PDF阅读器】  【关闭】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 2544次   下载 1986次 本文二维码信息
码上扫一扫!
靶向PreS1的HBV mRNA疫苗的开发与免疫原性评价
NarhPhilipAmor(阿莫)1,2,林昂1,2
字体:加大+|默认|缩小-
(1.中国药科大学基础医学与临床药学学院,江苏 南京 211198;2.中国药科大学新药安全评价研究中心,江苏 南京 211198)
摘要:
目的 通过靶向HBV PreS1抗原设计并制备具有强免疫原性的治疗性mRNA疫苗。方法 基于中国患者常见的GenotypeC-Adr亚型HBV毒株的PreS1抗原序列,并添加T7 RNA聚合酶启动子、UTR序列和分泌肽,设计并通过不同平台优化了mRNA疫苗序列。将体外转录的mRNA(2 μg/wells)转染到HEK293T细胞中,通过ELISA方法验证PreS1抗原的表达。将mRNA包封在LNP中,通过肌肉注射免疫小鼠。通过ELISA检测血清中的抗体水平,ELISPOT检测脾脏T细胞的抗原特异性应答验证mRNA疫苗的免疫原性。结果 与空白对照组相比,mRNA疫苗组小鼠血清中产生大量PreS1特异性IgG抗体(P<0.05)。ELISPOT结果显示,mRNA疫苗组脾脏T细胞对PreS1肽库刺激特异性产生IFNγ。结论 靶向PreS1的治疗性HBV mRNA疫苗具有良好的免疫原性,在小鼠体内诱导特异性B细胞反应(体液免疫)和T细胞反应(细胞免疫)。
关键词:  乙型肝炎病毒  治疗性mRNA疫苗  脂质纳米颗粒  免疫原性
DOI:10.13506/j.cnki.jpr.2024.11.001
基金项目:国家自然科学基金项目(No.32200764)
出版日期:2024-11-25
Development and evaluation of PreS1-targeted HBV mRNA vaccine
Narh Philip Amor1,2,LIN Ang1,2
(1.School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 211198, China; 2.Center for New Drug Safely Evaluation and Research, China Pharmaceutical University, Nanjing 211198, China)
Abstract:
Objective To design and develop a therapeutic mRNA vaccine encoding HBV PreS1 antigen with strong immunogenicity. Methods Based on the PreS1 antigen sequence of GenotypeC-Adr subtype HBV strains that commonly infect Chinese patients, mRNA vaccine sequences was designed and optimized using different platforms with the addition of T7 RNA polymerase promoter, UTR sequence, and signal peptide. The in-vitro transcribed mRNA (2 μg/well) was transfected into HEK293T cells, and PreS1 antigen expression was verified using ELISA. The mRNA was then efficiently encapsulated with an ionizable lipid-based LNP, and mice were immunized via intramuscular injection. Subsequently, antibody levels in serum were detected using ELISA, and antigen-specific responses of splenic T cells were validated by ELISPOT to assess the immunogenicity of the mRNA vaccine. Results Compared to the control group, mice in the mRNA vaccine groups showed significantly increased levels of PreS1-specific IgG antibodies in serum (P<0.05). The ELISPOT assay demonstrated that splenic T cells from the mRNA vaccine groups produced IFNγ in response to stimulation with PreS1 peptide pools. Conclusion The therapeutic HBV mRNA vaccine encoding PreS1 antigen exhibited robust immunogenicity, inducing specific B cell (humoral immunity) and T cell responses (cellular immunity) in mice.
Key words:  Hepatitis B virus  Therapeutic mRNA vaccine  Lipid nanoparticles  Immunogenicity
今日访问量:2471    总访问量:55338902
网站版权:《药学研究》编辑部     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
主办:山东省食品药品检验研究院、山东省药学会 地址:山东省济南市高新区新泺大街2749号 邮政编码:250101
电话:0531-81216586 电子邮箱:yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
技术支持:北京勤云科技有限公司